• Save
Pharma industry
Upcoming SlideShare
Loading in...5
×
 

Pharma industry

on

  • 3,884 views

 

Statistics

Views

Total Views
3,884
Views on SlideShare
3,884
Embed Views
0

Actions

Likes
1
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Pharma industry Pharma industry Presentation Transcript

  • By Abhishek Sharma Submitted To: RVM Finishing School & Consultancy
  •  Indian Pharmaceutical Evolution Pharmaceutical Market(CDSCO) Major Players SWOT Analysis GDP Relation Future Submitted To: RVM Finishing School & COnsultancy
  • Indian Pharmaceutical Industry Evolved in Five Phases Phase 1- Early Years (1950-1970) Foreign companies dominating the Market Absence of organized Indian companies Phase 2 – Government Control (1970-1980) Indian Patent Act-1970 Drug prices capped Local companies begin to make impact Submitted To: RVM Finishing School & COnsultancy
  •  Phase 3 – Development Phase (1980-1990) Development in process Infrastructure creation Initial stage of export market Phase 4 – Growth Phase (1990-2000) Expansion of domestic Market Development of international Market Development in research Phase 5 – Innovation and Research (2000-2010) IP law Discovery research Convergence Submitted To: RVM Finishing School & COnsultancy
  • Submitted To: RVM Finishing School & COnsultancy
  •  Industry size Rs. 1 Lakh Crs approx. ($20 bn.) and is growing at the rate of 14% Domestic market size stands at 58 Thousand Crs approx. equivalent to US $11.6 bn Export is approx Rs 42 Thousand Crs ($9 bn.)growing at the rate of 10% p.a. Import is approx Rs 12,500 Crs ($2.2 bn.) Submitted To: RVM Finishing School & COnsultancy
  •  India is 3rd largest in terms of volume 13th in terms of value Export of Biotech products and Biopharmaceuticals US $1.36 bn. India is 800 WHO-GMP certified and 172 US FDA Approvals along with 153 EDQM certified facilities India has the largest number of manufacturing facilities outside US Submitted To: RVM Finishing School & COnsultancy
  •  Drugs from India exported to more than 200 countries Vaccines from India are exported to more than 151 countries Submitted To: RVM Finishing School & COnsultancy
  •  Sun Pharma Sun Pharma has market Capitalization around Rs 73,018.88 Cr. Cipla Cipla has market capitalization of around Rs 33,280 Cr. Dr Reddys Labs Dr. Reddys Lab has market capitalization of around Rs 31,106.79 Cr. Lupin Lupin has market capitalization of Rs 26,196 Cr. Submitted To: RVM Finishing School & COnsultancy
  •  Strengths  Cost effective  Strong Manufacturing Base  Ability of high quality skilled workforce  Excellent marketing and distribution network  Diverse ecosystem Weakness  Less investment is research and development  Lack of coordination between industry and academic  Negligible expenditure on healthcare in the country  Manufacturing of fake and low quality medicines Submitted To: RVM Finishing School & COnsultancy
  •  Opportunities  Increased export potential  Marketing tie ups with multinational companies to sell their products in domestic market  Immense scope to position India as a centre for international clinical trials  Key player in global pharmaceutical R&D  Export of generic drugs to developed market Submitted To: RVM Finishing School & COnsultancy
  •  Threats  Product patent regime is a major threat to domestic industry unless the industry takes up R&D initiative aggressively  Drug price control order puts undue pressure on product prices, affecting the profitability of pharmaceutical companies.  The new MRP based excise duty regime threatens the business of smaller pharmaceutical companies Submitted To: RVM Finishing School & COnsultancy
  •  Pharma industry generally grows at about 1.5-1.6 times the Gross Domestic Product Globally, India ranks third in terms of manufacturing Pharma products by volume According to a study by FICCI-Ernst & Young India will open a probable US$ 8 billion market for MNCs selling expensive drugs by 2015 The study also says that the domestic Pharma market is likely to reach US$ 20 billion by 2015 Submitted To: RVM Finishing School & COnsultancy
  •  The Minister of Commerce estimates that US$ 6.31 billion will be invested in the domestic pharmaceutical sector Public spending on healthcare is likely to raise from 7 per cent of GDP in 2007 to 13 per cent of GDP by 2015 Dr Reddys Laboratories has tied up with GlaxoSmithKline to develop and market generics and formulations in upcoming markets overseas. Due to the low cost of R&D, the Indian pharmaceutical off-shoring industry is designated to turn out to be a US$ 2.5 billion opportunity by 2012 Submitted To: RVM Finishing School & COnsultancy
  • Thank You Submitted To: RVM Finishing School & COnsultancy